Antimicrobial Resistance (AMR): What You Need to Know to Keep Yourself and Your Family Safe

Fast Facts: What You Need to Know About Antimicrobial Resistance (AMR)
November 22, 2021
Clinically Speaking: Important Questions to Ask About Antimicrobial Resistance
November 22, 2021

Antibiotics have no effect against a virus, yet most of us have been prescribed antibiotics for viral conditions like cold symptoms or bronchial infections at some point. While that practice might have seemed harmless, decades of overuse and misuse of antimicrobials have contributed to antimicrobial resistance (AMR), which is when germs change over time and no longer respond to common medications.

Each year, more than 2.8 million antibiotic-resistant infections occur in the United States alone, and more than 35,000 people die as a result of AMR. The situation has become so serious that the World Health Organization declared AMR a top global health threat facing humanity.

What can you do to keep your family safe? In our new education program, we share the facts you need to know and the questions to ask your healthcare provider about AMR. We also turned to Dr. Maria Isabel Rosas Garcia, a pediatric infectious disease specialist, to explain more about why AMR should be taken seriously and what you can do to fight this growing health concern.

Finally, we invite you to tune into our webinar, “Antimicrobial Resistance: The Global Threat and Why Women Need to Know About It” to hear from leading experts about the basics of AMR, how we need to raise awareness, appropriate use of antibiotics, what women can do for themselves and their family, and why to become active in the policy campaign.


Thomas Heymann, President & CEO, Sepsis Alliance


Helen Boucher, MD, FACP, FIDSA, Attending Physician, Faculty, Tufts Center for Integrated Management of Antimicrobial Resistance; Dean Ad Interim and Professor of Medicine, Tufts University School of Medicine

Sandy Cayo, DNP FNP-BC, VP of Clinical Performance and Transformation, New Jersey Hospital Association

Amanda Jesek, Senior Vice President, Public Policy & Government Relations, Infectious Diseases Society of America

Kevin Outterson, Professor of Law, Boston University; N. Neal Pike Scholar in Health and Disability Law; Executive Director of CARB-X

This resource was created with support from Pfizer Inc.